ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1613

Anti-Malarial Drugs (hydroxychloroquine and quinacrine) Decrease The Production Of Interferon-Alfa Initiated By TLR-9 Agonist

Ou Jin1, Xi Zhang1, Qiuxia Li1, Lingkai Fang1, Hongyue Huang1, Chengcheng Hou1, Zetao Liao1, Qiujing Wei1, Zhiming Lin2, Dongfang Lin1 and Jieruo Gu3, 1Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, 2Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, 3Medicine, Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Antimalarial drugs, interferons, systemic lupus erythematosus (SLE) and toll-like receptors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects II: Central Nervous System Manifestations, Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Toll-like receptor 9 (TLR-9) plays an important role in initiating innate immunity.  The recognition of self DNA fragments by TLR-9 may results in the production of interferon-α, a central cytokine in the pathogenesis of Systemic lupus erythematosus (SLE). Anti-malarial drugs such as hydroxychloroquine (HCQ) and quinacrine (Qn) are commonly used in the treatment of SLE. Some studies imply that anti-malarial drugs may influence TLR pathway, though detail mechanisms are still under study. In this study, we want to evaluate the influence of anti-malarial drugs (HCQ and Qn) on the initiation of IFN-α production through TLR-9 pathway, combinded with or without glucocorticoid.

Methods:

Freshly isolated PBMCs of healthy donors were stimulated with the TLR-9 agonist CpG oligodeoxynucleotides (CpG-A ODN)-2216, then incubated with different kinds of anti-malarial drugs ( HCQ and Qn or both) and / or different doses of glucocorticoid (hydrocortisone: 10-6M (low dose), 10-5M (median dose), 10-4M (high dose), 10-3M (pulse dose)). The changes in the expression of IFN-α were detected by real time PCR.

Results:

 (1). Hydroxychloroquine or quinacrine alone or combined together significantly inhibited the production of IFN-α initiated by ODN 2216 (Qn (p=0.047), HCQ (p=0.047), Qn and HCQ (p=0.046)). (2). When combined with low (10-6M), median (10-5M), or high (10-4M) dose of hydrocortisone, HCQ or Qn or both significantly revised the elevation of IFN-α caused by ODN 2216 ((low dose: Qn (p=0.017), HCQ (p=0.017), Qn & HCQ (p=0.017), median dose: Qn (p=0.034), HCQ (p=0.032), Qn & HCQ (p=0.036), high dose: Qn (p=0.028), HCQ (p=0.024), Qn & HCQ (p=0.028)), which cannot be decreased by glucocorticoid (each p>0.05). (3). When combined with pulse dose (10-3M) hydrocortisone which could promote the expression of IFN-α to some extent, anti-malarial drugs (HCQ, Qn alone or both) could not significantly down-regulate the expression of IFN-α stimulated by ODN 2216.

Conclusion:

(1). Anti-malarial drugs hamper the production of IFN-α by TLR-9 recognition of nucleotides (ODN 2216), which is the critical cytokine in the pathogenesis of lupus. (2). The combination with anti-malarial drugs (HCQ, Qn alone or both) seem to be a good choice to help low, median, high dose glucocorticoid to achieve a better disease control by inhibiting IFN-α, which cannot be decreased by glucocorticoid. (3). When combined with pulse dose glucocorticoid, anti-malarial drugs (HCQ, Qn alone or both) could not down-regulate the expression of IFN-α stimulated by TLR-9 agonist.


Disclosure:

O. Jin,
None;

X. Zhang,
None;

Q. Li,
None;

L. Fang,
None;

H. Huang,
None;

C. Hou,
None;

Z. Liao,
None;

Q. Wei,
None;

Z. Lin,
None;

D. Lin,
None;

J. Gu,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-malarial-drugs-hydroxychloroquine-and-quinacrine-decrease-the-production-of-interferon-alfa-initiated-by-tlr-9-agonist/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology